Biogen tries out mefloquine as treatment for PML; Aveo deal
Biogen Idec is testing an old malaria drug in the hope that it can treat the rare but deadly brain disease linked to its multiple sclerosis drug Tysabri.
Read MoreAuthor: Kevin Grogan
Controversial Ranbaxy plant approved by UK, Australia
India’s Ranbaxy Laboratories says that regulators in the UK and Australia have given a clean bill of health to its facility at Paonta Sahib, the company’s manufacturing plant which has been accused of falsifying data by the US Food and Drug Administration.
Read MoreNycomed contemplates possible sale, claims WSJ
Switzerland’s Nycomed has reportedly asked Goldman Sachs to explore a possible sale of the company which could bring in as much as 10 billion euros.
Read MoreMerck & Co “targeted” by US government over Vioxx
Merck & Co has been advised that “it is a target” of a grand jury investigation related to its activities in connection with the withdrawn painkiller Vioxx.
Read MoreMerck KGaA sets up 40 millon euro venture capital fund
Merck KGaA has unveiled plans for a “strategic, corporate venture capital fund” which will invest in emerging biotechnology companies.
Read More- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
